Imunon Q1 net loss narrows to $5.6M; cash runway into 2025; PLACCINE IND planned Q4 2023

Imunon, Inc.

2024-Q1 EPS reported -$0.68

Net loss of $5.6M ($0.68/share) vs $10.5M ($1.82/share) in Q1 2022; operating expenses down 5% to $5.7M.
Cash and equivalents $37.3M at March 31, 2023; expects funding operations into 2025, plus $1.9M in NJ NOL sales.
Phase 1/2 trial of IMNN-001 + Avastin in advanced ovarian cancer opened for enrollment at MD Anderson and others.
Pre-IND consultation filed with FDA for PLACCINE COVID-19 booster; IND expected Q4 2023.
Collaborated with Wistar Institute to develop PLACCINE vaccines for infectious diseases.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Imunon, Inc. reported financial results for the three months ended March 31, 2023.

Period: the three months ended March 31, 2023
Result: reported results

Exact text from the filing

IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the three months ended March 31, 2023

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Imunon, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-016286

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.